Effect of a Food Supplement with Natural Extracts of Cocoa, Amaranth Seed and Ginger in Overweight or Obese Patients
NCT ID: NCT06769035
Last Updated: 2025-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
40 participants
INTERVENTIONAL
2023-08-20
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Cocoa Flavanols on Pulmonary Oxygen Uptake Kinetics and Exercise Tolerance in Sedentary Middle-aged Adults
NCT04370353
Efficacy and Safety of Zingiber Officinale Roscoe Extract on Body Fat
NCT03260751
Pharmacokinetics Assessing Bioavailability of Gingerols and Shogaols of Five Ginger Extracts
NCT03698318
Evaluation of New Beverages Rich in Bioactive Compounds for the Modulation of Energetic Metabolism in Overweight Adults
NCT04016337
Determination of the Independent Effects of Beetroot Juice Components, Dietary Nitrate and Antioxidants, on Exercise Tolerance and Health Benefits in Individuals With Obesity
NCT03545009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The solution to the consequences of obesity and overweight, low-grade inflammation, oxidative stress and insulin sensitivity are based on pharmaceutical treatments and surgical processes, but changes in lifestyle are the cornerstone of treatment, however the patient's adherence to treatment is low and the results are long-term, for this reason some authors have dedicated themselves to looking for alternatives that complement changes in lifestyle and improve health status.
Polyphenols are bioactive compounds that have been shown to influence insulin resistance, oxidative stress and inflammation. There is extensive evidence from clinical studies and meta-analyses in overweight patients to support the effects of this study's supplement on waist circumference, weight, BMI, blood pressure, insulin sensitivity, markers of inflammation, and oxidative stress.
Cocoa has been positioned as a preventive phytopharmaceutical due to its polyphenolic compounds, mainly flavonols with anti-inflammatory and antioxidant effects, which can help prevent or delay the complications of DM2 by modulating insulin secretion.
Amaranth seed is a source of protein, calcium, iron, dietary fiber, vitamin E and D, with a high content of monounsaturated fats and polyunsaturated fatty acids such as squalene, which have been given anti-inflammatory and antioxidant properties, Mozak and collaborators in 2018 did a clinical trial with amaranth seed in overweight patients with favorable results in reducing fasting insulin and the HOMA-IR index.
Ginger has been widely studied due to its potential in reducing glucose, lipid and body fat levels, and has been used as a preventative in chronic diseases. A clinical trial conducted in 2019 by Rahimlou and collaborators included 37 participants with metabolic syndrome, significantly decreased fasting glucose levels and improved insulin resistance.
The objective of the present study is to evaluate the effect of a supplement with cocoa, amaranth seed and ginger in overweight patients on inflammation, insulin resistance and oxidative stress.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Food supplement: cocoa, amaranth seed and ginger
Group A:
20g Cocoa, 10g amaranth seed and 1g ginger once a day for 12 weeks
Cocoa, amaranth seed and ginger
Sachet with 20gr of cocoa, 10g of amaranth seed and 1g of ginger, one dose per day for 12 weeks
Food supplement: cocoa
Group B:
20g Cocoa once a day for 12 weeks
Cocoa
Sachet with 20gr of cocoa one dose per day for 12 weeks
Food supplement: amaranth
Group C:
10g Amaranth seed once a day for 12 weeks
Amaranth seed
Sachet with 10g of amaranth seed one dose per day for 12 weeks
Food supplement: placebo
Group D:
Coloring and flavoring, one dose per day for 12 weeks
Placebo
Sachet with coloring and flavoring, one dose per day for 12 weeks one dose per day for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cocoa, amaranth seed and ginger
Sachet with 20gr of cocoa, 10g of amaranth seed and 1g of ginger, one dose per day for 12 weeks
Amaranth seed
Sachet with 10g of amaranth seed one dose per day for 12 weeks
Cocoa
Sachet with 20gr of cocoa one dose per day for 12 weeks
Placebo
Sachet with coloring and flavoring, one dose per day for 12 weeks one dose per day for 12 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men or women;
3. Age between 18 and 60 years;
4. Waist circumference ≥ 88 cm in women or ≥ 94 cm in men;
5. Plus one of the following criteria:
* BMI \>25 kg/m2 and not \> 30 kg/m2 in both genders or history of bariatric surgery \> 6 months;
* Fasting serum glucose of 100-125 mg/dL or HbA1c of 5.7-6.4% or on pharmacological treatment with OAD for prediabetes;
* Insulin resistance by HOMA \> 2.6 and insulin sensitivity by QUICKI \<0.34;F.
* Negative pregnancy test.
Exclusion Criteria
2. Routine use of antioxidants in the last 3 months;
3. BMI ≥ 30 kg/m2 or recent bariatric surgery (\< 6 months);
4. LDL cholesterol \> 160 mg/dL or total cholesterol \> 200 mg/dL, and no treatment for dyslipidemia;
5. Major micro or macrovascular complications due to severe metabolic disease (history of acute coronary syndrome, cerebrovascular disease, peripheral arterial insufficiency or aortic aneurysm);
6. Pregnancy or breastfeeding;
7. Refusal to use an effective contraceptive method for the duration of the study;
8. Hypersensitivity to any of the components of the formula or phenylketonurics;
9. Endocrinological or rheumatic diseases;
10. Patient with recent initiation of vigorous physical exercise or exercise routine for weight loss and/or;
11. Liver or kidney failure by clinical and/or laboratory criteria.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Guadalajara
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luis Miguel Román Pintos
Doctor in pharmacology and internist. Professor at University of Guadalajara
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidad de Guadalajara
Guadalajara, Jalisco, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.